Drug Reimportation: Prescription, Placebo, or Poison?

DSpace/Manakin Repository

Drug Reimportation: Prescription, Placebo, or Poison?

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Thierault, Rene J. en_US
dc.date.accessioned 2012-06-07T05:14:31Z
dc.date.issued 2002 en_US
dc.identifier.citation Drug Reimportation: Prescription, Placebo, or Poison? (2002 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8846805
dc.description.abstract This paper examines drug reimportation as a means of reducing prescription drug prices paid by U.S. consumers. Specifically, this paper examines the provisions of the MEDS Act of 2000, which was passed by Congress right before the 2000 election. The purpose of the legislation is to allow pharmacists and wholesalers to import drugs from countries that sell them for less than in the United States (often due to price controls), and to pass those savings on to the consumers, perhaps remaining as a permanent check on pharmaceutical prices. Two Secretaries of Health and Human Services have since declined to implement the legislation, however, due to concerns for the safety risks of U.S. consumers, and concerns that consumers would not realize significant savings. This paper will examine the safety and cost saving concerns raised by the Secretaries of HHS. Regarding safety, this paper concludes that the MEDS Act significantly loosens the protections of the Prescription Drug Marketing Act (PDMA), and would undermine the safety and effectiveness of the U.S. drug supply, particularly in light of ongoing concerns regarding bioterrorism, counterfeiting and diversion. Regarding prices, this paper examines the economics behind pricing in the pharmaceutical industry and concludes that drug reimportation would not provide significant cost savings to U.S. consumers, and could have a number of unintended consequences. Overall, this paper concludes that drug reimportation is an unsound policy, both due to economic and safety concerns. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject drug reimportation en
dc.subject MEDS en
dc.subject policy en
dc.subject regulation en
dc.title Drug Reimportation: Prescription, Placebo, or Poison? en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-06-07T05:14:31Z

Files in this item

Files Size Format View
theriault.pdf 3.172Kb PDF View/Open
theriault.rtf 252.3Kb RTF file View/Open
theriault.html 199.7Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters